Pillar guide — primary care pharmacy
The definitive UK guide to medicines optimisation in NHS primary care
Definition
What medicines optimisation actually means in 2026
Medicines optimisation is the patient-centred discipline of ensuring every person on medication gets the best possible outcome from their treatment — safe, effective, evidence-based, and aligned to what matters to them. It is the operating philosophy that replaced the older, system-centred "medicines management" model when the Royal Pharmaceutical Society published the Four Principles in 2013 and NICE codified them in guideline NG5 the following year.
In NHS primary care in 2026, medicines optimisation is delivered as a connected workflow: cohort identification by pharmacy technicians, IP-led Structured Medication Reviews, structured high-risk drug monitoring, embedded deprescribing for frailty and over-75s, 7-day discharge reconciliation, prescribing safety alert response, and quantified reporting to the PCN Clinical Director and ICB MO team. The PCN Network Contract DES makes it the highest-value workstream the PCN owns.
This pillar guide and the 23 cluster pages beneath it describe what good medicines optimisation looks like — by audience, by intervention, by population and by governance lens — drawing on NICE NG5/NG56/NG197, the RPS framework, PrescQIPP, the MHRA Yellow Card scheme and live PCN delivery.
What good MO delivers
Outcomes a well-run PCN MO programme produces in year one
The four principles
RPS Medicines Optimisation — the operating principles
- Principle 1: Aim to understand the patient's experience of taking medicines
- Principle 2: Evidence-based choice of medicines (NICE, BNF, local formulary)
- Principle 3: Ensure medicines use is as safe as possible
- Principle 4: Make medicines optimisation part of routine practice — not a one-off project
Cluster contents
The 23 deep-dive pages underneath this pillar
For GP Practices
Practical medicines optimisation at single-practice scale.
For PCNs
Network-scale delivery aligned to the PCN DES.
For ICBs
Population-level commissioning, formulary and prescribing safety.
For Care Homes
Enhanced Health in Care Homes medicines optimisation.
Structured Medication Reviews
The flagship DES intervention — cohort, conduct and code.
Polypharmacy
Problematic polypharmacy identification and review.
Deprescribing
Safe, evidence-based stopping of unnecessary medicines.
Medicines Reconciliation
Discharge and transfer of care within 7 days.
Repeat Prescribing
Optimising the highest-volume prescribing process in general practice.
High-Risk Drugs
DMARDs, lithium, amiodarone, anticoagulants — structured monitoring.
Prescribing Safety
MHRA alerts, NRLS learning, PINCER and SEA at PCN scale.
Antimicrobial Stewardship
TARGET, ESPAUR and ICB AMS programmes in primary care.
Controlled Drugs
CD governance, accountable officer reporting, opioid stewardship.
Cost & Savings
Prescribing efficiency without compromising care.
Biosimilars & Switches
Therapeutic and biosimilar switching at PCN scale.
Formulary Adherence
Driving Joint Formulary compliance through PCN-level audit.
Frailty & Over-75s
STOPP/START, anticholinergic burden and frailty MO.
Long-Term Conditions
Hypertension, T2DM, CVD, asthma/COPD MO at scale.
Governance & Supervision
What ICBs audit and what CQC asks for.
KPIs & Reporting
The MO dashboard every PCN Clinical Director should hold.
NICE & Frameworks
NG5, NG56, RPS Four Principles and PrescQIPP mapped to delivery.
ROI & Impact
What MO is worth — measurable outcomes for PCNs and ICBs.
Shared Decision Making
NICE NG197 in primary care MO practice.
Frequently asked questions
Medicines optimisation — FAQs
What is medicines optimisation in the NHS?+
Medicines optimisation is a patient-centred approach to ensuring people get the best possible outcomes from their medicines. NICE NG5 and the RPS framework define it through four principles: understand the patient experience, evidence-based choice, safety, and routine practice. In primary care it is delivered through SMRs, high-risk drug monitoring, polypharmacy reviews, reconciliation, deprescribing and prescribing safety work.
Who is responsible for medicines optimisation in a PCN?+
Operationally it sits with the PCN clinical pharmacist team supported by a pharmacy technician, supervised by a lead pharmacist or GP partner, and accountable to the PCN Clinical Director. Strategic priorities flow from the ICB medicines optimisation team via the Joint Formulary, prescribing safety alerts and DES targets.
How is medicines optimisation funded?+
The workforce is reimbursed via the ARRS under the PCN Network Contract DES. Activity sits inside the SMR & Medicines Optimisation service specification of the DES, with additional incentives via QOF, IIF where applicable, and ICB-led commissioning for prescribing safety and cost programmes.
What is the difference between medicines management and medicines optimisation?+
Medicines management is a process-focused, organisation-centred view (formulary control, cost containment, prescribing systems). Medicines optimisation is the outcome-focused, patient-centred evolution introduced by the RPS in 2013 and embedded in NICE NG5 — it asks whether each patient is getting the best possible outcome from their medicines, not just whether the system is well-run.
What does good medicines optimisation look like in 2026?+
Proactive cohort identification, IP-led SMRs, structured high-risk drug monitoring, embedded deprescribing for over-75s, robust discharge reconciliation within 7 days, prescribing safety alert closure to ICB timelines, and quantified KPI reporting to the PCN Clinical Director and ICB MO team.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.